Segall Bryant & Hamill LLC Makes New Investment in LivaNova PLC $LIVN

Segall Bryant & Hamill LLC bought a new stake in shares of LivaNova PLC (NASDAQ:LIVN) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,457 shares of the company’s stock, valued at approximately $665,000.

Other large investors have also recently made changes to their positions in the company. Hantz Financial Services Inc. lifted its stake in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the last quarter. State of Wyoming purchased a new position in LivaNova in the second quarter valued at about $31,000. EverSource Wealth Advisors LLC grew its stake in LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the last quarter. Quarry LP bought a new position in LivaNova in the third quarter worth about $36,000. Finally, Covestor Ltd raised its holdings in LivaNova by 108.6% in the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after purchasing an additional 392 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

More LivaNova News

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Quarterly results exceeded expectations: LivaNova reported second-quarter earnings of $1.26 per share, versus the $1.08–$1.09 analyst consensus, while revenue rose 10.8% year over year to $390.6 million, above the approximately $380.5 million estimate. LivaNova Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: 2026 earnings guidance was raised: The company now expects full-year adjusted EPS of $4.30 to $4.40, above the $4.15 consensus estimate. Revenue guidance was approximately $1.5 billion, broadly in line with expectations. LivaNova exceeds second-quarter forecasts and increases 2026 outlook
• Positive Sentiment: Analyst became more bullish: Needham raised its price target from $81 to $93 and assigned a Buy rating, implying meaningful potential upside from the referenced trading level. Benzinga
• Neutral Sentiment: Momentum has been strong: LivaNova recently reached a fresh 52-week high, but commentary noted that investors must weigh the company’s improving fundamentals against the possibility that additional gains are already reflected in the valuation. LivaNova Hits Fresh High
• Negative Sentiment: Shares pulled back despite the beats: The decline following the earnings release may reflect profit-taking after the recent rally, or investor concern that the roughly 40 times earnings valuation leaves limited room for further upside unless growth accelerates.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a report on Wednesday. KeyCorp boosted their price objective on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, June 22nd. Mizuho increased their target price on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Barclays raised their target price on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Finally, Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, LivaNova presently has a consensus rating of “Moderate Buy” and an average price target of $83.50.

LivaNova Stock Down 8.4%

NASDAQ:LIVN opened at $78.14 on Thursday. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. LivaNova PLC has a twelve month low of $45.64 and a twelve month high of $85.76. The company has a market cap of $4.29 billion, a PE ratio of 40.07 and a beta of 0.86. The company’s 50 day moving average is $79.54 and its two-hundred day moving average is $70.61.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.08 by $0.18. The business had revenue of $390.59 million during the quarter, compared to the consensus estimate of $380.34 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.05 earnings per share. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. Analysts anticipate that LivaNova PLC will post 3.73 EPS for the current year.

Insiders Place Their Bets

In other news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. This represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.35% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.